Physical Medicine and Rehabilitation for Complex Regional Pain Syndromes Medication

  • Author: Manish K Singh, MD; Chief Editor: Rene Cailliet, MD   more...
 
Updated: May 5, 2011
 

Medication Summary

Multiple classes of medications have been tried for patients with CRPS, often with variable results and generally with limited published research to help clinicians predict which patients will respond well to a particular medication.[26]

Analgesic drug therapy for CRPS can be divided into the following categories:

Opioid analgesics

  • Opioids are used commonly as an analgesic for many pain syndromes.
  • Opioid therapy can be a safe and good option in patients with intractable nonmalignant pain and no history of drug abuse.
  • Quang-Cantagrel and colleagues reported that failure of one opioid cannot predict the patient's response to another opioid.[27]
  • High doses of tramadol may provide effective and safe relief in neuropathic pain, including allodynia.

Nonopioid analgesics (eg, NSAIDs, acetaminophen)

  • Acetaminophen is a safe choice for treatment of pain during pregnancy and breastfeeding.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) are discussed in further detail within the tables below.

Antidepressants

Antidepressant medications play a major role in treatment of neuropathic pain.

  • Tricyclic antidepressants:
    • Amitriptyline (Elavil)
    • Imipramine (Tofranil)
    • Doxepin (Sinequan)
    • Clomipramine (Anafranil)
    • Nortriptyline (Pamelor)
  • Selective serotonin reuptake inhibitor (SSRI) antidepressants:
    • Paroxetine (Paxil)
    • Fluoxetine (Prozac)
    • Sertraline (Zoloft)
    • Escitalopram (Lexapro)
  • Other antidepressants:
    • Nefazodone (Serzone)
    • Venlafaxine (Effexor)
    • Duloxetine (Cymbalta)
    • Bupropion (Wellbutrin)

Anticonvulsants

  • Sodium channel antagonists have been used in the management of neuropathic pain for several years.
  • These medications are started slowly and are administered as needed.
  • The patient is monitored carefully.
  • Use of several anticonvulsant drugs (eg, pregabalin, carbamazepine, phenytoin, sodium valproate, clonazepam, topiramate, lamotrigine) has been tried in the treatment of RSD.
  • In studies by Nicholson and by Rowbothan and colleagues, gabapentin has been reported to be effective in the management of chronic neuropathic pain syndromes.[28]
  • Controlled studies for the effect of lamotrigine have not become available yet, but Jain notes that the drug has shown effect in neuropathic pain.
  • Ziconotide may be useful in the future for neuropathic pain, as Jain notes that it has a favorable risk/benefit ratio, with advantages over several currently available intrathecal therapies for pain.[29]

Other adjunct analgesics

  • Hewitt states that N -methyl-D-aspartate (NMDA) – receptor antagonists, including ketamine and dextromethorphan, may have potential as co-analgesics when used in combination with opioids. Some studies have shown that ketamine infusion therapy provides effective pain relief and does not have adverse cognitive effects with extended use.[30, 31]
  • Benzodiazepines, baclofen, and tizanidine may be helpful in decreasing spasm and providing pain relief.
  • Corticosteroid, mexiletine (orally active class Ib anti-arrhythmic agent), nifedipine (calcium channel blocker), propranolol (beta blocker), phenoxybenzamine (alpha blocker), and clonidine (alpha2-adrenergic agonist) are other alternatives. Some drug trials provided consistent support for analgesia with corticosteroids in the early stage and may have long-term effectiveness.
  • Lidoderm 5% patches are sometimes helpful in decreasing allodynia and providing pain relief.
  • Although it has not been approved by the Food and Drug Administration (FDA) for this indication, botulinum toxin can be considered for dystonia seen in patients with RSD.
Next

Nonsteroidal anti-inflammatory drugs

Class Summary

These inhibit inflammatory reactions and pain by decreasing activity of cyclo-oxygenase, which is responsible for prostaglandin synthesis. NSAIDs may provide pain relief in the early stage of RSD.

View full drug information

Ibuprofen (Motrin, Advil)

 

NSAIDs are used commonly for patients with mild to moderate pain. Inhibit inflammatory reactions and pain by decreasing prostaglandin synthesis.

View full drug information

Naproxen sodium (Anaprox, Naprelan, Naprosyn)

 

For relief of mild to moderate pain; inhibits inflammatory reactions and pain by decreasing activity of cyclo-oxygenase, which results in a decrease of prostaglandin synthesis.

Previous
Next

Antidepressants

Class Summary

These drugs increase the synaptic concentration of serotonin and/or norepinephrine in the CNS by inhibiting their re-uptake by the presynaptic neuronal membrane. Similar agents that can be helpful are duloxetine (Cymbalta) and venlafaxine (Effexor).

View full drug information

Nortriptyline (Pamelor)

 

Has demonstrated effectiveness in the treatment of chronic and neuropathic pain.

View full drug information

Amitriptyline (Elavil)

 

Has demonstrated effectiveness in certain chronic and neuropathic pain.

View full drug information

Duloxetine (Cymbalta)

 

Indicated for diabetic peripheral neuropathic pain. Potent inhibitor of neuronal serotonin and norepinephrine reuptake.

Previous
Next

Anticonvulsants

Class Summary

Use of certain anti-epileptic drugs, such as the GABA analogue gabapentin (Neurontin), has proven helpful in some cases of neuropathic pain. Other anticonvulsant drugs (eg, carbamazepine, phenytoin, sodium valproate or clonazepam, topiramate, lamotrigine, zonisamide, tiagabine) also have been tried in RSD.

View full drug information

Gabapentin (Neurontin)

 

Has anticonvulsant properties and antineuralgic effects; however, exact mechanism of action is unknown. Structurally related to GABA but does not interact with GABA receptors.

View full drug information

Pregabalin (Lyrica)

 

Structural derivative of GABA. Mechanism of action unknown. Binds with high affinity to alpha 2 -delta site (a calcium channel subunit). In vitro, reduces calcium-dependent release of several neurotransmitters, possibly by modulating calcium channel function. FDA approved for neuropathic pain associated with diabetic peripheral neuropathy or postherpetic neuralgia and as adjunctive therapy in partial-onset seizures.

Previous
Next

Opioid analgesics

Class Summary

These commonly used analgesics are employed for many pain syndromes.

View full drug information

Oxycodone (OxyContin)

 

Currently, the long-acting form of opioids is commonly used in initial and later stages of RSD. Start with a small dose and increase gradually.

View full drug information

Morphine sulfate (MS Contin, Avinza, Kadian, Duramorph, Astramorph)

 

DOC for analgesia due to reliable and predictable effects, safety profile, and ease of reversibility with naloxone. Various IV doses are used; commonly titrated until desired effect obtained.

View full drug information

Fentanyl transdermal patch (Duragesic)

 

Potent narcotic analgesic with much shorter half-life than morphine sulfate. Excellent choice for pain management and sedation with short duration (30-60 min) and easy to titrate. Easily and quickly reversed by naloxone.

When using transdermal dosage form, most patients are controlled with 72 h dosing intervals; however, some patients may require dosing intervals of 48 h.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Manish K Singh, MD  Assistant Professor, Department of Neurology, Teaching Faculty for Pain Management and Neurology Residency Program, Hahnemann University Hospital, Drexel College of Medicine; Medical Director, Neurology and Pain Management, Jersey Institute of Neuroscience

Manish K Singh, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Pain Medicine, American Association of Physicians of Indian Origin, American Headache Society, American Medical Association, and American Society of Regional Anesthesia and Pain Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Jashvant Patel, MD  Medical Director, Department of Pain Medicine and Comprehensive Rehabilitation, Medical College of Pennsylvania Hahnemann University

Jashvant Patel, MD is a member of the following medical societies: Alberta Medical Association, American Academy of Pain Medicine, American Academy of Physical Medicine and Rehabilitation, American Medical Association, American Society of Regional Anesthesia and Pain Medicine, and Medical Society of the State of New York

Disclosure: Nothing to disclose.

John Grothusen, PhD  Director of Quantitative Sensory and Autonomic Nervous System Laboratory, Associate Professor, Department of Neurology, Drexel University College of Medicine

Disclosure: Nothing to disclose.

Patrick M Foye, MD  Associate Professor of Physical Medicine and Rehabilitation, Co-Director of Musculoskeletal Fellowship, Co-Director of Back Pain Clinic, Director of Coccyx Pain Service (Tailbone Pain Service: www.TailboneDoctor.com), University of Medicine and Dentistry of New Jersey, New Jersey Medical School

Patrick M Foye, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, American Association of Neuromuscular and Electrodiagnostic Medicine, Association of Academic Physiatrists, and International Spine Intervention Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Robert J Kaplan, MD  James E Van Zandt VA Medical Center, Staff Physician, Department of Rehabilitation Medicine

Robert J Kaplan, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Senior Pharmacy Editor, eMedicine

Disclosure: eMedicine Salary Employment

Patrick M Foye, MD  Associate Professor of Physical Medicine and Rehabilitation, Co-Director of Musculoskeletal Fellowship, Co-Director of Back Pain Clinic, Director of Coccyx Pain Service (Tailbone Pain Service: www.TailboneDoctor.com), University of Medicine and Dentistry of New Jersey, New Jersey Medical School

Patrick M Foye, MD is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, American Association of Neuromuscular and Electrodiagnostic Medicine, Association of Academic Physiatrists, and International Spine Intervention Society

Disclosure: Nothing to disclose.

Kelly L Allen, MD  Medical Director, Medevals

Disclosure: Nothing to disclose.

Chief Editor

Rene Cailliet, MD  Professor-Chairman Emeritus, Department of Rehabilitation Medicine, University of Southern California School of Medicine; Former Director, Department of Rehabilitation Medicine, Santa Monica Hospital Medical Center

Rene Cailliet, MD is a member of the following medical societies: American Academy of Pain Medicine, American Academy of Physical Medicine and Rehabilitation, American Pain Society, Association of American Medical Colleges, International Association for the Study of Pain, and Pan American Medical Association

Disclosure: Nothing to disclose.

References

  1. Paice E. Reflex sympathetic dystrophy. BMJ. Jun 24 1995;310(6995):1645-8. [Medline]. [Full Text].

  2. Uceyler N, Eberle T, Rolke R, et al. Differential expression patterns of cytokines in complex regional pain syndrome. Pain. Sep 2007;[Medline].

  3. Wasner G, Heckmann K, Maier C, et al. Vascular abnormalities in acute reflex sympathetic dystrophy (CRPS I): complete inhibition of sympathetic nerve activity with recovery. Arch Neurol. May 1999;56(5):613-20. [Medline]. [Full Text].

  4. Kurvers HA, Jacobs MJ, Beuk RJ, et al. The spinal component to skin blood flow abnormalities in reflex sympathetic dystrophy. Arch Neurol. Jan 1996;53(1):58-65. [Medline].

  5. Blaes F, Tschernatsch M, Braeu ME, Matz O, Schmitz K, Nascimento D. Autoimmunity in complex-regional pain syndrome. Ann N Y Acad Sci. Jun 2007;1107:168-73. [Medline].

  6. Veldman PH, Reynen HM, Arntz IE, Goris RJ. Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients. Lancet. Oct 23 1993;342(8878):1012-6. [Medline].

  7. Maleki J, LeBel AA, Bennett GJ, et al. Patterns of spread in complex regional pain syndrome, type I (reflex sympathetic dystrophy). Pain. Dec 1 2000;88(3):259-66. [Medline].

  8. Peterlin BL, Rosso AL, Nair S, et al. Migraine may be a risk factor for the development of complex regional pain syndrome. Cephalalgia. Jul 9 2009;[Medline].

  9. Werner R, Davidoff G, Jackson MD, et al. Factors affecting the sensitivity and specificity of the three-phase technetium bone scan in the diagnosis of reflex sympathetic dystrophy syndrome in the upper extremity. J Hand Surg [Am]. May 1989;14(3):520-3. [Medline].

  10. Kozin F, Soin JS, Ryan LM, et al. Bone scintigraphy in the reflex sympathetic dystrophy syndrome. Radiology. Feb 1981;138(2):437-43. [Medline]. [Full Text].

  11. Schürmann M, Zaspel J, Löhr P, et al. Imaging in early posttraumatic complex regional pain syndrome: a comparison of diagnostic methods. Clin J Pain. Jun 2007;23(5):449-57. [Medline].

  12. Bruehl S, Lubenow TR, Nath H, Ivankovich O. Validation of thermography in the diagnosis of reflex sympathetic dystrophy. Clin J Pain. Dec 1996;12(4):316-25. [Medline].

  13. Chelimsky TC, Low PA, Naessens JM, et al. Value of autonomic testing in reflex sympathetic dystrophy. Mayo Clin Proc. Nov 1995;70(11):1029-40. [Medline].

  14. Brunnekreef JJ, Oosterhof J, Wolff AP, et al. No impaired hemoglobin oxygenation in forearm muscles of patients with chronic CRPS-1. Clin J Pain. Jul-Aug 2009;25(6):513-9. [Medline].

  15. Rashiq S, Galer BS. Proximal myofascial dysfunction in complex regional pain syndrome: a retrospective prevalence study. Clin J Pain. Jun 1999;15(2):151-3. [Medline].

  16. Steverens VL, Oerlemans HM, Weesels A. Cost effectiveness analysis of adjuring physical or occupational therapy for patients with RSD. Arch Phys Med Rehabilitation. 1999;80:1038-43.

  17. Johnston EC, Howell SJ. Tension neuropathy of the superficial peroneal nerve: associated conditions and results of release. Foot Ankle Int. Sep 1999;20(9):576-82. [Medline].

  18. Eckmann MS, Ramamurthy S, Griffin JG. Intravenous regional ketorolac and lidocaine in the treatment of complex regional pain syndrome of the lower extremity: a randomized, double-blinded, crossover study. Clin J Pain. Mar-Apr 2011;27(3):203-6. [Medline].

  19. Kumar K, Nath RK, Toth C. Spinal cord stimulation is effective in the management of reflex sympathetic dystrophy. Neurosurgery. Mar 1997;40(3):503-8; discussion 508-9. [Medline].

  20. van Hilten BJ, van de Beek WJ, Hoff JI, et al. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med. Aug 31 2000;343(9):625-30. [Medline]. [Full Text].

  21. Lundborg C, Dahm P, Nitescu P, et al. Clinical experience using intrathecal (IT) bupivacaine infusion in three patients with complex regional pain syndrome type I (CRPS-I). Acta Anaesthesiol Scand. Jul 1999;43(6):667-78. [Medline].

  22. Dielissen PW, Claassen AT, Veldman PH, Goris RJ. Amputation for reflex sympathetic dystrophy. J Bone Joint Surg Br. Mar 1995;77(2):270-3. [Medline]. [Full Text].

  23. Monti DA, Herring CL, Schwartzman RJ, et al. Personality assessment of patients with complex regional pain syndrome type I. Clin J Pain. Dec 1998;14(4):295-302. [Medline].

  24. Hassenbusch SJ, Stanton-Hicks M, Schoppa D, et al. Long-term results of peripheral nerve stimulation for reflex sympathetic dystrophy. J Neurosurg. Mar 1996;84(3):415-23. [Medline].

  25. Zollinger PE, Tuinebreijer WE, Breederveld RS, et al. Can vitamin C prevent complex regional pain syndrome in patients with wrist fractures? A randomized, controlled, multicenter dose-response study. J Bone Joint Surg Am. Jul 2007;89(7):1424-31. [Medline].

  26. Hsu ES. Practical management of complex regional pain syndrome. Am J Ther. Mar-Apr 2009;16(2):147-54. [Medline].

  27. Quang-Cantagrel ND, Wallace MS, Magnuson SK. Opioid substitution to improve the effectiveness of chronic noncancer pain control: a chart review. Anesth Analg. Apr 2000;90(4):933-7. [Medline]. [Full Text].

  28. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. Dec 2 1998;280(21):1837-42. [Medline].

  29. Jain KK. An evaluation of intrathecal ziconotide for the treatment of chronic pain. Expert Opin Investig Drugs. Oct 2000;9(10):2403-10. [Medline].

  30. Kiefer RT, Rohr P, Ploppa A, et al. Complete recovery from intractable complex regional pain syndrome, CRPS-type I, following anesthetic ketamine and midazolam. Pain Pract. Jun 2007;7(2):147-50. [Medline].

  31. Koffler SP, Hampstead BM, Irani F, et al. The neurocognitive effects of 5 day anesthetic ketamine for the treatment of refractory complex regional pain syndrome. Arch Clin Neuropsychol. Aug 2007;22(6):719-29. [Medline].

  32. Dumitru D. Reflex sympathetic dystrophy. Phys Med Rehabil: State Art Rev. 1991;5:89-101.

  33. Baron R. Peripheral neuropathic pain: from mechanisms to symptoms. Clin J Pain. Jun 2000;16(2 Suppl):S12-20. [Medline].

  34. Baron R, Maier C. Reflex sympathetic dystrophy: skin blood flow, sympathetic vasoconstrictor reflexes and pain before and after surgical sympathectomy. Pain. Oct 1996;67(2-3):317-26. [Medline].

  35. Bhatia KP, Bhatt MH, Marsden CD. The causalgia-dystonia syndrome. Brain. Aug 1993;116 ( Pt 4):843-51. [Medline].

  36. Blanchard J, Ramamurthy S, Walsh N, et al. Intravenous regional sympatholysis: a double-blind comparison of guanethidine, reserpine, and normal saline. J Pain Symptom Manage. Dec 1990;5(6):357-61. [Medline].

  37. Brown DL. Somatic or sympathetic block for reflex sympathetic dystrophy. Which is indicated?. Hand Clin. Aug 1997;13(3):485-97. [Medline].

  38. Bruehl S, Harden RN, Galer BS, et al. External validation of IASP diagnostic criteria for Complex Regional Pain Syndrome and proposed research diagnostic criteria. International Association for the Study of Pain. Pain. May 1999;81(1-2):147-54. [Medline].

  39. Clinchot DM, Lorch F. Sympathetic skin response in patients with reflex sympathetic dystrophy. Am J Phys Med Rehabil. Jul-Aug 1996;75(4):252-6.

  40. Cohen JS. Erythromelalgia: new theories and new therapies. J Am Acad Dermatol. Nov 2000;43(5 Pt 1):841-7. [Medline].

  41. Davis MD, O'Fallon WM, Rogers RS 3rd, Rooke TW. Natural history of erythromelalgia: presentation and outcome in 168 patients. Arch Dermatol. Mar 2000;136(3):330-6. [Medline]. [Full Text].

  42. Galer BS, Bruehl S, Harden RN. IASP diagnostic criteria for complex regional pain syndrome: a preliminary empirical validation study. International Association for the Study of Pain. Clin J Pain. Mar 1998;14(1):48-54. [Medline].

  43. [Best Evidence] Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. Jul 2005;116(1-2):109-18. [Medline].

  44. Harden RN. A clinical approach to complex regional pain syndrome. Clin J Pain. Jun 2000;16(2 Suppl):S26-32. [Medline].

  45. Hewitt DJ. The use of NMDA-receptor antagonists in the treatment of chronic pain. Clin J Pain. Jun 2000;16(2 Suppl):S73-9. [Medline].

  46. Hopp J, Schwartzman RJ, Grothusen J. Increased sensory thresholds in patients with reflex sympathetic dystrophy. Neurology. Feb 1996;46 A:227.

  47. Hord ED, Oaklander AL. Complex regional pain syndrome: a review of evidence-supported treatment options. Curr Pain Headache Rep. Jun 2003;7(3):188-96. [Medline].

  48. Kemler MA, Barendse GA, van Kleef M, et al. Spinal cord stimulation in patients with chronic reflex sympathetic dystrophy. N Engl J Med. Aug 31 2000;343(9):618-24. [Medline]. [Full Text].

  49. Kemler MA, van de Vusse AC, van den Berg-Loonen EM, et al. HLA-DQ1 associated with reflex sympathetic dystrophy. Neurology. Oct 12 1999;53(6):1350-1. [Medline].

  50. Kingery WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain. Nov 1997;73(2):123-39. [Medline].

  51. Kurvers HA, Jacobs MJ, Beuk RJ, et al. Reflex sympathetic dystrophy: evolution of microcirculatory disturbances in time. Pain. Mar 1995;60(3):333-40. [Medline].

  52. Linson MA, Leffert R, Todd DP. The treatment of upper extremity reflex sympathetic dystrophy with prolonged continuous stellate ganglion blockade. J Hand Surg [Am]. Mar 1983;8(2):153-9. [Medline].

  53. Merskey H, Bogduk N. Classification of Chronic Pain, Description of Chronic Pain Syndrome and Definitions of Pain Terms. Seattle, Wash: IASP Press; 1994.

  54. Norton JV, Zager E, Grady JF. Erythromelalgia: diagnosis and classification. J Foot Ankle Surg. May-Jun 1999;38(3):238-41. [Medline].

  55. Ochoa JL. Reflex sympathetic dystrophy: a disease of medical understanding. Clin J Pain. Dec 1992;8(4):363-6; discussion 367-9. [Medline].

  56. Pak TJ, Martin GM, Magness JL, et al. Reflex sympathetic dystrophy. Review of 140 cases. Minn Med. May 1970;53(5):507-12. [Medline].

  57. Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain. May 1986;25(2):171-86. [Medline].

  58. Rommel O, Tegenthoff M, Pern U, et al. Sympathetic skin response in patients with reflex sympathetic dystrophy. Clin Auton Res. Sep 1995;5(4):205-10. [Medline].

  59. Schwartzman RJ. Explaining reflex sympathetic dystrophy. Arch Neurol. May 1999;56(5):521-2. [Medline].

  60. Schwartzman RJ. New treatments for reflex sympathetic dystrophy. N Engl J Med. Aug 31 2000;343(9):654-6. [Medline].

  61. Schwartzman RJ, Kerrigan J. The movement disorder of reflex sympathetic dystrophy. Neurology. Jan 1990;40(1):57-61. [Medline].

  62. Schwartzman RJ, Liu JE, Smullens SN, et al. Long-term outcome following sympathectomy for complex regional pain syndrome type 1 (RSD). J Neurol Sci. Sep 10 1997;150(2):149-52. [Medline].

  63. Schwartzman RJ, Maleki J. Postinjury neuropathic pain syndromes. Med Clin North Am. May 1999;83(3):597-626. [Medline].

  64. Stanton-Hicks M, Baron R, Boas R, et al. Complex regional pain syndromes: guidelines for therapy. Clin J Pain. Jun 1998;14(2):155-66. [Medline].

  65. Stanton-Hicks M, Janig W, Hassenbusch S, et al. Reflex sympathetic dystrophy: changing concepts and taxonomy. Pain. Oct 1995;63(1):127-33. [Medline].

  66. Tahmoush AJ, Schwartzman RJ, Hopp JL, et al. Quantitative sensory studies in complex regional pain syndrome type 1/RSD. Clin J Pain. Dec 2000;16(4):340-4. [Medline].

  67. van der Laan L, Veldman PH, Goris RJ. Severe complications of reflex sympathetic dystrophy: infection, ulcers, chronic edema, dystonia, and myoclonus. Arch Phys Med Rehabil. Apr 1998;79(4):424-9. [Medline].

  68. Wasner G, Backonja MM, Baron R. Traumatic neuralgias: complex regional pain syndromes (reflex sympathetic dystrophy and causalgia): clinical characteristics, pathophysiological mechanisms and therapy. Neurol Clin. Nov 1998;16(4):851-68. [Medline].

  69. Wechsler RJ, Frank ED, Halpern EH, et al. Percutaneous lumbar sympathetic plexus catheter placement for short- and long-term pain relief: CT technique and results. J Comput Assist Tomogr. Jul-Aug 1998;22(4):518-23. [Medline].

  70. Wilder RT, Berde CB, Wolohan M, et al. Reflex sympathetic dystrophy in children. Clinical characteristics and follow-up of seventy patients. J Bone Joint Surg Am. Jul 1992;74(6):910-9. [Medline].

  71. Zollinger PE, Tuinebreijer WE, Kreis RW, et al. Effect of vitamin C on frequency of reflex sympathetic dystrophy in wrist fractures: a randomised trial. Lancet. Dec 11 1999;354(9195):2025-8. [Medline].

 
Previous
Next
 
A 29-year-old woman with reflex sympathetic dystrophy in the right foot demonstrates discoloration of the skin and marked allodynia.
This photo shows the same patient as in the above image, following a right lumbar sympathetic block. Marked increase in the temperature of the right foot is noted, with more than 50% pain relief.
A 68-year-old woman with complex regional pain syndrome type II (causalgia).
A 36-year-old woman with right arm reflex sympathetic dystrophy and dystonic posture (movement disorder).
Normal laser Doppler study of the upper extremities. When the patient performs inspiratory gasp repeatedly during laser Doppler image acquisition, the transient capillary flow decreases are displayed easily and dramatically (as dark bands) in the pseudocolor image.
Laser Doppler study of the upper extremities in a patient with right hand reflex sympathetic dystrophy.
Laser Doppler study of the lower extremities in a 25-year-old woman with reflex sympathetic dystrophy in the right foot.
Algorithm for the management of chronic regional pain syndrome (CRPS). Resolution of this syndrome does not commonly occur, and the patient will need chronic pain management.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.